With participants safety paramount, PAREXEL Early Phase has developed a superior range of services for the conduct of first-in-man - or first-in-human (FiH) - and other Phase I safety studies giving you the assurance that your compound will move into human testing swiftly and safely.
Many of our units are based directly within hospitals providing direct emergency room access to offer you the best possible environment for the performance of first-in-human and other Phase I safety studies. Additionally, all of our units have well documented emergency procedures, a high ratio of medical doctors to beds and highly experienced nursing teams. With over 30 years experience in performing Phase I trials, we provide our clients with the clinical pharmacology, scientific and clinical expertise that they need - practical advice, sound protocol design, quality data and the assurance of the smoothest possible transition into the clinical phase of development.
We are a leading global bio/pharmaceutical services organization that helps clients expedite time-to-market through our development and launch services. These include a broad range of clinical development capabilities, integrated advanced technologies, regulatory affairs consulting, and commercialization services.